See you tomorrow at #ASGCT23! We’re excited to share new data from our lead program targeting 𝘈𝘉𝘊𝘈4 retinopathies.

At 9am PT, #TeamAscidian’s Head of Research will present on how we’re #RewritingRNA for the treatment of #Stargardt disease.
👉 https://bit.ly/3MBG592

[Automatic repost https://twitter.com/dystobot/status/1659239978839179269]

RT @drecwalsh: Last up Terry Flotte on Tay Sachs/ Sandhoff AAVrh8 equimolar mixture of HexA / HexB constructs
Juveniles enrolled but future will limit to infants.
All juveniles had dystonia, unclear if disease or therapy related.

Next trial will be bicistronic vector.

#ASGCT23 https://t.co/WoftEypzKo